B+
Bull case
25%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-06-09 · RankAlpha Sentiment Codex
PETS
PetMed ExpressCNasdaq / Consumer Discretionary Distribution & Retail
Last Price
Quote time unavailable
Current thesis
The bull case is a stabilization story: Q4 showed a modest sequential sales increase, management says cost structure and operating processes were reset, and future upside would come from better customer retention plus B2B/membership/white-label growth [#SEC-8K-2026-06-02].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Adjusted EBITDA stayed negative at $(15.4)m for FY26, so the business has not yet proven operating leverage [#SEC-8K-2026-06-02].
Momentum
83
Value
33
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.85 · Bull $2.75 · Bear $0.95Analysis 2026-06-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $2.15
Why
Momentum83 · Δ7d -
Value33 · Δ7d 0.0
Sentiment60 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Adjusted EBITDA stayed negative at $(15.4)m for FY26, so the business has not yet proven operating leverage [#SEC-8K-2026-06-02].
- • Management’s recovery plan depends on customer retention, membership/B2B expansion, and white-label fulfillment execution, which remain unproven [#SEC-8K-2026-06-02].
- • The bear case is that the core business still shrank sharply in FY26, with revenue down 21.1% and adjusted EBITDA still negative; if prescription medication declines persist or retention/B2B initiatives stall, the turnaround thesis loses credibility [#SEC-8K-2026-06-02].
Catalyst clock
2026-06-02
Fiscal Q4/FY26 print shows lower sales but some sequential stabilization
Lead driver: Sentiment · See AI snapshot
Momentum
83
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
33
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.7
Sentiment
60
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 82.7 / Value 33.1 / Sentiment 60.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.85
Analysis reference price unavailable
Analysis 2026-06-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-06-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$37.94M
Beta
0.71
Shares Out
21.68M
P/E (TTM)
238.6
P/S (TTM)
0.36
P/FCF (TTM)
80.00
Rev YoY
-19.9%
EPS YoY
-82.8%
Gross Margin
+22.4%
Op Margin
-18.2%
Net Debt
-$20.88M
Current Ratio
0.68
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data